KR20160122829A - Ｈｅｒ2/ｎｅｕ 과발현 종양의 치료를 위한 조성물 및 방법 - Google Patents

Ｈｅｒ2/ｎｅｕ 과발현 종양의 치료를 위한 조성물 및 방법 Download PDF

Info

Publication number
KR20160122829A
KR20160122829A KR1020167025517A KR20167025517A KR20160122829A KR 20160122829 A KR20160122829 A KR 20160122829A KR 1020167025517 A KR1020167025517 A KR 1020167025517A KR 20167025517 A KR20167025517 A KR 20167025517A KR 20160122829 A KR20160122829 A KR 20160122829A
Authority
KR
South Korea
Prior art keywords
her2
neu
another embodiment
listeria
recombinant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020167025517A
Other languages
English (en)
Korean (ko)
Inventor
바파 샤하비
아누 왈레챠
파울로 씨. 마시아그
이본느 패터슨
니콜라 메이슨
매튜 시비
Original Assignee
어드박시스, 인크.
더 트러스티스 오브 더 유니버시티 오브 펜실바니아
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/189,008 external-priority patent/US20150366955A9/en
Priority claimed from US14/268,436 external-priority patent/US20140234370A1/en
Application filed by 어드박시스, 인크., 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 filed Critical 어드박시스, 인크.
Priority to KR1020247007406A priority Critical patent/KR20240038103A/ko
Publication of KR20160122829A publication Critical patent/KR20160122829A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020167025517A 2014-02-25 2015-02-25 Ｈｅｒ2/ｎｅｕ 과발현 종양의 치료를 위한 조성물 및 방법 Ceased KR20160122829A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020247007406A KR20240038103A (ko) 2014-02-25 2015-02-25 Ｈｅｒ2/ｎｅｕ 과발현 종양의 치료를 위한 조성물 및 방법

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US14/189,008 2014-02-25
US14/189,008 US20150366955A9 (en) 2009-11-11 2014-02-25 Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors
US14/268,436 2014-05-02
US14/268,436 US20140234370A1 (en) 2009-11-11 2014-05-02 Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors
US201462076411P 2014-11-06 2014-11-06
US62/076,411 2014-11-06
PCT/US2015/017559 WO2015130810A2 (en) 2014-02-25 2015-02-25 Compositions and methods for the treatment of her2/neu over-expressing tumors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020247007406A Division KR20240038103A (ko) 2014-02-25 2015-02-25 Ｈｅｒ2/ｎｅｕ 과발현 종양의 치료를 위한 조성물 및 방법

Publications (1)

Publication Number Publication Date
KR20160122829A true KR20160122829A (ko) 2016-10-24

Family

ID=54009773

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020167025517A Ceased KR20160122829A (ko) 2014-02-25 2015-02-25 Ｈｅｒ2/ｎｅｕ 과발현 종양의 치료를 위한 조성물 및 방법
KR1020247007406A Pending KR20240038103A (ko) 2014-02-25 2015-02-25 Ｈｅｒ2/ｎｅｕ 과발현 종양의 치료를 위한 조성물 및 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020247007406A Pending KR20240038103A (ko) 2014-02-25 2015-02-25 Ｈｅｒ2/ｎｅｕ 과발현 종양의 치료를 위한 조성물 및 방법

Country Status (12)

Country Link
EP (1) EP3110942A4 (enExample)
JP (1) JP2017507943A (enExample)
KR (2) KR20160122829A (enExample)
CN (1) CN106661538A (enExample)
AU (1) AU2015223136A1 (enExample)
BR (1) BR112016019534A2 (enExample)
CA (1) CA2940646A1 (enExample)
IL (1) IL247436A0 (enExample)
MX (1) MX2016011114A (enExample)
RU (1) RU2016137834A (enExample)
SG (1) SG11201607036XA (enExample)
WO (1) WO2015130810A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9012141B2 (en) 2000-03-27 2015-04-21 Advaxis, Inc. Compositions and methods comprising KLK3 of FOLH1 antigen
WO2012125551A1 (en) 2011-03-11 2012-09-20 Advaxis Listeria-based adjuvants
AU2013232291B8 (en) 2012-03-12 2016-07-21 Advaxis, Inc. Suppressor cell function inhibition following listeria vaccine treatment
EP3107566A4 (en) 2014-02-18 2017-10-11 Advaxis, Inc. Biomarker directed multi-target immunotherapy
BR112016020364A2 (pt) * 2014-03-05 2018-01-16 Advaxis, Inc. métodos para suscitar uma resposta de uma célula t antitumoral em um indivíduo tendo um tumor ou câncer e para aumentar a razão de células t efetoras sobre células t reguladoras no baço de um indivíduo
CA2946716A1 (en) 2014-04-24 2015-10-29 Advaxis, Inc. Recombinant listeria vaccine strains and methods of producing the same
MA41644A (fr) 2015-03-03 2018-01-09 Advaxis Inc Compositions à base de listeria comprenant un système d'expression de minigènes codant pour des peptides, et leurs procédés d'utilisation
SG11201804957VA (en) 2015-12-16 2018-07-30 Gritstone Oncology Inc Neoantigen identification, manufacture, and use
SG11201901979SA (en) 2016-11-30 2019-04-29 Advaxis Inc Immunogenic compositions targeting recurrent cancer mutations and methods of use thereof
US11179339B2 (en) 2017-09-19 2021-11-23 Advaxis, Inc. Compositions and methods for lyophilization of bacteria or listeria strains
EP4576103A3 (en) 2017-10-10 2025-08-27 Gritstone bio, Inc. Neoantigen identification using hotspots
KR20200090855A (ko) 2017-11-22 2020-07-29 그릿스톤 온콜로지, 인코포레이티드 신생항원에 대한 접합 에피토프 제시 감소

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6855320B2 (en) * 2000-03-29 2005-02-15 The Trustees Of The University Of Pennsylvania Fusion of non-hemolytic, truncated form of listeriolysin O to antigens to enhance immunogenicity
US9017660B2 (en) * 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors

Also Published As

Publication number Publication date
WO2015130810A3 (en) 2016-01-28
BR112016019534A2 (pt) 2017-10-24
JP2017507943A (ja) 2017-03-23
EP3110942A4 (en) 2017-08-30
EP3110942A2 (en) 2017-01-04
AU2015223136A1 (en) 2016-09-22
IL247436A0 (en) 2016-11-30
NZ723750A (en) 2024-02-23
KR20240038103A (ko) 2024-03-22
CA2940646A1 (en) 2015-09-03
CN106661538A (zh) 2017-05-10
RU2016137834A (ru) 2018-03-29
SG11201607036XA (en) 2016-09-29
WO2015130810A2 (en) 2015-09-03
MX2016011114A (es) 2017-02-20

Similar Documents

Publication Publication Date Title
KR20160122829A (ko) Ｈｅｒ2/ｎｅｕ 과발현 종양의 치료를 위한 조성물 및 방법
AU2022200643B2 (en) Listeria-based compositions comprising a peptide minigene expression system and methods of use thereof
JP6039669B2 (ja) Ｈｅｒ２／ｎｅｕ発現腫瘍に対する薬剤の調製における弱毒化組換えリステリアの使用
JP5985397B2 (ja) 組換えリステリア株およびそれを含む免疫原性組成物
KR20170002552A (ko) Her-2-양성 암 치료용 병용 면역 치료 및 방사선 치료
AU2013232291B2 (en) Suppressor cell function inhibition following listeria vaccine treatment
US20140234370A1 (en) Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors
US20160361401A1 (en) Compositions and methods for the treatment of her2/neu over-expressing tumors
KR20160130774A (ko) 바이오마커 지도된 다중-표적 면역치료
US20150196628A1 (en) Combination immuno therapy and radiotherapy for the treatment of her-2-positive cancers
JP2016222715A (ja) 血管新生因子を含む組成物およびその使用方法
AU2016369580A1 (en) Listeria-based immunotherapy and methods of use thereof
KR20220116191A (ko) 4-1bbl 아쥬반트화 재조합 변형 백시니아 바이러스 앙카라 (mva)의 의약적 용도
JP6329211B2 (ja) 脳腫瘍または乳腺腫瘍の発症を遅延させるための医薬の製造における組換えリステリア株の使用
TW201707715A (zh) 用於治療ｈｅｒ－２陽性癌症之組合免疫療法及放射線療法
HK1197584A (en) Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

PX0601 Decision of rejection after re-examination

St.27 status event code: N-2-6-B10-B17-rex-PX0601

X601 Decision of rejection after re-examination
T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

J201 Request for trial against refusal decision
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PJ1301 Trial decision

St.27 status event code: A-3-3-V10-V15-crt-PJ1301

Decision date: 20251022

Appeal event data comment text: Appeal Kind Category : Appeal against decision to decline refusal, Appeal Ground Text : 2016 7025517

Appeal request date: 20240305

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2024101000541